Clinical Trials on PID in Ireland

Total 20 results

Spectranetics Corporation

Recruiting

Tack Optimized Balloon Angioplasty Post-Market Study (TOBA PMS)

Peripheral Arterial Disease | Peripheral Vascular Diseases | PAD | PAD - Peripheral Arterial Disease | Dissection | Arterial Dissection

United States
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Gardia Medical

Completed

Evaluation of WIRION™ EPS in Lower Extremities Arteries (WISE-LE)

Peripheral Arterial Disease (PAD)

United States, Germany
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
Cordis Corporation
Massachusetts General Hospital; Prairie Education and Research Cooperative

Completed

Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System (OPEN)

Cardiovascular Diseases | Peripheral Vascular Disease | Peripheral Artery Disease | Vascular Disease | PAD

United States, Belgium
AbbVie

Completed

COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel (COSMOS)

Parkinson's Disease (PD)

Austria, Canada, Croatia, Czechia, Greece, Hungary, Ireland, Israel, Romania, Spain, Sweden
Adamas Pharmaceuticals, Inc.

Completed

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (EASE LID)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia (LID)

United States, Canada
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. (ALLAY-LID-I)

Parkinson's Disease | Levodopa Induced Dyskinesias (LID)

France, Spain, Germany, Canada, United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID (ALLAY-LID-II)

Parkinson's Disease | Levodopa Induced Dyskinesia (LID)

France, Germany, Canada, United States, Spain
Forest Laboratories

Completed

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Autistic Disorder | Autism | Autism Spectrum Disorders | Asperger Syndrome | Asperger's Disorder | Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, France, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine
Forest Laboratories

Completed

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Belgium, Colombia, Estonia, Hungary, Iceland, Italy, Korea, Republic of, New Zealand, Poland, Serbia, South Africa, Spain, Ukraine, Australia, Canada, France, Singapore
Forest Laboratories

Terminated

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Autistic Disorder | Autism | Asperger's Disorder | Autism Spectrum Disorder (ASD) | Asperger's | Pediatric Autism | Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

United States, Estonia, Hungary, Iceland, Italy, Korea, Republic of, Serbia, Ukraine, Canada, Colombia, Belgium, France, New Zealand, Poland, South Africa, Spain
ACADIA Pharmaceuticals Inc.

Completed

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

United States
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Gilead Sciences
Merck Sharp & Dohme LLC

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)

Triple Negative Breast Cancer | PD-L1 Positive

United States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

Triple Negative Breast Cancer | PD-L1 Negative

United States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
Hoffmann-La Roche

Completed

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

China, United States, Spain, Netherlands, Canada, France, Mexico, Poland, Hungary, Australia, Denmark, United Kingdom, Czech Republic
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Autoimmune Diseases | Hodgkin Lymphoma | Hematologic Malignancies | Acute Lymphoblastic Leukemia (ALL) | Non-hodgkin Lymphoma | Severe Aplastic Anemia | Inherited Disorders of Metabolism | Inherited Abnormalities of Platelets | Histiocytic Disorders | Acute Myelogenous Leukemia (AML or ANLL) | Other Acute... and other conditions

United States

Clinical Trials on PID in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations